PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Disease overview • Introduction • Pathophysiology • Symptoms • Management • Epidemiology PART 06: Product portfolio of approved therapies PART 07: Pipeline analysis • OHR-102 • RTH258 • Fovista • RG7716 • PF-04523655 • NT-503 • LFG316 • REGN2176-3 • Zimura • LHA510 • DE-120 PART 08: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 09: Market segmentation by ROA • IV • Intravitreal PART 10: Geographical segmentation • Global choroidal neovascularization market by geographical segmentation 2015-2020 • Choroidal neovascularization market in Americas • Choroidal neovascularization market in EMEA • Choroidal neovascularization market in APAC PART 11: Market drivers • Growing older population • Increased prevalence of chronic diseases • High patient and physician satisfaction • Increase in diagnosis rate PART 12: Impact of drivers PART 13: Market challenges • High cost of treatment • Limited public awareness • Side effects associated with treatment options • Availability of alternative therapies PART 14: Impact of drivers and challenges PART 15: Market trends • Strategic alliances and M&A • Increased initiatives and programs • Use of combination therapies • Increase in R&D PART 16: Vendor landscape • Competitive scenario • Market analysis 2015 • F. Hoffmann-La Roche • Novartis • Regeneron Pharmaceuticals • Bayer HealthCare • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio   List of Exhibits Exhibit 01: Product offerings 7 Exhibit 02: Key buying criteria for choroidal neovascularization drugs Exhibit 03: Types of choroidal neovascularization Exhibit 04: Symptoms of choroidal neovascularization Exhibit 05: Treatment options for choroidal neovascularization Exhibit 06: Pipeline portfolio: Global choroidal neovascularization therapeutics Exhibit 07: Global choroidal neovascularization market 2015-2020 ($ billions) Exhibit 08: Five forces analysis Exhibit 09: Segmentation of global choroidal neovascularization market by ROA 2015 Exhibit 10: Market segmentation by geography 2015 Exhibit 11: Choroid neovascularization market revenue by geography 2015-2020 ($ billions) Exhibit 12: Choroidal neovascularization market in Americas 2015-2020 ($ billions) Exhibit 13: Choroidal neovascularization market in EMEA 2015-2020 ($ billions) Exhibit 14: Choroidal neovascularization market in APAC 2015-2020 ($ millions) Exhibit 15: Global choroidal neovascularization market: YoY growth and revenue based on geography 2015-2020 Exhibit 16: Impact of drivers Exhibit 17: Impact of drivers and challenges Exhibit 18: Vendor ranking of global choroidal neovascularization market 2015 Exhibit 19: Roche: YoY growth and revenue of Avastin 2011-2014 ($ billions) Exhibit 20: Roche: YoY growth and revenue of Lucentis 2011-2014 ($ billions) Exhibit 21: Roche: Key takeaways Exhibit 22: Novartis' specialty ophthalmic segmentation by revenue 2014 Exhibit 23: Novartis: YoY revenue and growth rate of Lucentis (excluding the US) 2012-2014 ($ millions) Exhibit 24: Novartis: Key takeaways Exhibit 25: Regeneron: YoY revenue and growth rate of EYLEA (in the US) 2012-2014 ($ billions) Exhibit 26: Regeneron Pharmaceuticals: Key takeaways Exhibit 27: Bayer HealthCare: YoY revenue and growth rate of EYLEA 2012-2014 ($ millions) Exhibit 28: Bayer HealthCare: Key takeaways

Bayer HealthCare, Novartis, Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Alcon, Allergan, Avalanche, Bausch and Lomb, Gilead Sciences, Iconic Therapeutics, Lpath, Neurotech Pharmaceuticals, Ohr Pharmaceutical, Opthea, Ophthotech, PanOptica, Pfizer, Promedior, QLT, Quark, Resolvyx Pharmaceuticals, RXi Pharmaceuticals, Sagent Pharmaceuticals, Santen, Sanwa Kagaku Kenkyusho.